Patent · US Active

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

US11084884B2 · kind B2 · utility

14Cited by

8References

17Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Daniel J. Sexton · Melrose, US
Burt Adelman · Concord, US
Yung Chyung · Lexington, US
Christopher TenHoor · Hopkinton, US
Jon A. Kenniston · Hingham, US
Ryan Faucette · Melrose, US
Ryan Iarrobino · Sterling, US
Joseph Biedenkapp · Newton, US

Key dates

Filing date	Jan 21, 2015
Grant date	Aug 10, 2021
Priority date	—
Expiry date	Jul 11, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.